Spruce Biosciences (SPRB) Income from Continuing Operations (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Income from Continuing Operations of 21637000.0 for Q1 2026, down 52.38% year-over-year from 45440580.24 in Q1 2025, and down 94.51% quarter-over-quarter from 11124000.0 in Q4 2025.
Spruce Biosciences (SPRB) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Income from Continuing Operations for 8 consecutive years, with 21637000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 52.38% year-over-year to 21637000.0; the TTM figure through Mar 2026 stood at 43040000.0 (up 22.49% YoY), while the FY2025 annual figure was 38634000.0, up 27.21% from the prior year.
- Income from Continuing Operations fell to 21637000.0 in Q1 2026 per SPRB's latest filing, from 11124000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2067000.0 in Q2 2025 and bottomed at 23477000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 12300000.0 across 5 years, with a median of 12165000.0 in 2022.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 108.37% — and 2025, when it surged 77.49%.
- Spruce Biosciences' Income from Continuing Operations stood at 10099000.0 in 2022, then fell by 11.57% to 11267000.0 in 2023, then plunged by 108.37% to 23477000.0 in 2024, then jumped by 52.62% to 11124000.0 in 2025, then slumped by 94.51% to 21637000.0 in 2026.
- Business Quant data shows SPRB's Income from Continuing Operations at 21637000.0 in Q1 2026, 11124000.0 in Q4 2025, and 8212000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | -16.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.26 Mn |
| Mar 31, 2026 | -21.64 Mn |
| Dec 31, 2025 | -11.12 Mn |
| Sep 30, 2025 | -8.21 Mn |
| Jun 30, 2025 | -2.07 Mn |
| Mar 31, 2025 | -14.20 Mn |
| Dec 31, 2024 | -23.48 Mn |
| Sep 30, 2024 | -8.67 Mn |
| Jun 30, 2024 | -9.18 Mn |
| Mar 31, 2024 | -11.63 Mn |
| Dec 31, 2023 | -11.27 Mn |
| Sep 30, 2023 | -13.73 Mn |
| Jun 30, 2023 | -13.97 Mn |
| Mar 31, 2023 | -13.05 Mn |
| Dec 31, 2022 | -10.10 Mn |
| Sep 30, 2022 | -12.17 Mn |
| Jun 30, 2022 | -12.44 Mn |
| Mar 31, 2022 | -12.19 Mn |
| Dec 31, 2021 | -9.62 Mn |
| Sep 30, 2021 | -18.50 Mn |